Summary of the Conference Call for Kangfang Biotech Company Overview - **Company**: Kangfang Biotech - **Date**: August 6, 2025 Key Points Industry and Company Focus - Kangfang Biotech has strategically shifted focus from PD-1 monoclonal antibodies to bispecific antibodies as limitations of PD-1 therapies become apparent, showcasing its market foresight and strategic vision [2][3] - The company has demonstrated exceptional R&D efficiency, with all early-stage innovative drugs successfully advancing to commercialization or registration clinical stages, particularly core products AK104 and AK112, which have surpassed domestic average development speeds [2][3] Product Development and Clinical Trials - AK112 has shown outstanding performance in clinical trials for first-line wild-type non-small cell lung cancer (NSCLC), with the Harmony II study indicating a 49% reduction in progression and mortality risk compared to K drug, without significant increase in severe adverse reactions [4][13] - AK112 is being tested across multiple indications, including triple-negative breast cancer, biliary cancer, pancreatic cancer, and colorectal cancer, aiming to cover more patient groups who cannot use PD-1 inhibitors or have poor responses [4][19] Internationalization Achievements - Kangfang Biotech has made significant strides in international development, including licensing its monoclonal antibody to Merck in 2015 and a $5 billion exclusive licensing deal with Summit for Ivosidenib in 2022, marking a record for Chinese innovative drug out-licensing [6] - The company’s PD-1 monoclonal antibody received FDA approval in April 2025, becoming the first innovative biopharmaceutical independently developed by a Chinese company to achieve this milestone [6] Market Potential and Competitive Advantage - The second-generation immuno-oncology (IO) market is projected to be 3 to 4 times larger than the PD-1/PD-L1 inhibitor market, with AK112 positioned as a first-mover with significant value potential [2][7] - AK112's unique tetravalent structure enhances affinity for PD-1 and VEGF, significantly improving related signaling pathway effects and demonstrating superior safety in clinical trials compared to monoclonal antibodies or monoclonal antibody-VEGF combinations [11] Future Development and Market Outlook - The market is expected to focus on AK112's overseas clinical layout and collaboration progress in 2025, with potential for re-licensing or acquisition impacting asset revaluation [7] - The overall market for PD-1/PD-L1 inhibitors is projected to exceed $90 billion by 2028, with second-generation IO drugs potentially surpassing $300 billion in market size [9] Financial Projections - AK104 is expected to exceed 4 billion RMB in risk-adjusted peak sales in China, while AK112 could reach 8.5 billion RMB domestically and $23.3 billion in overseas markets, leading to a total valuation exceeding $200 billion for Kangfang Biotech [28][29] Pipeline and Future Innovations - Kangfang Biotech is not limited to bispecific antibodies but is also developing a range of candidates, including dual-target ADCs and other innovative therapies across various indications, indicating a robust pipeline for future growth [25][26] Conclusion - Kangfang Biotech's strategic pivot towards bispecific antibodies, strong R&D capabilities, international partnerships, and a promising pipeline position it favorably within the rapidly evolving oncology market, with significant growth potential anticipated in the coming years [2][29]

Summary of Conference Call Records Industry Overview - The Chinese innovative pharmaceutical industry is experiencing accelerated development, driven by internationalization, policy support, and technological breakthroughs [3][4] - The recognition of Chinese innovative drugs in international markets is increasing, with a notable rise in BD (business development) transactions and large upfront payments [1][3] Key Companies Innovent Biologics (信达生物) - Sales revenue from tumor products has rapidly increased, surpassing 8 billion RMB in 2024 and expected to reach 11 billion RMB in 2025 [1] - IBI363 shows significant efficacy in lung cancer and colorectal cancer, with a 12-month overall survival (OS) rate of 70.9% in lung cancer patients [7][8] - The company has a strong competitive advantage in the tumor field, with multiple potential products and a robust pipeline [9] - Non-tumor products like Masudutai and others are also entering the sales phase, with peak sales expected to exceed 8 billion RMB [10] Kangfang Biopharma (康方生物) - Revenue growth is projected to exceed 70% in 2025 and around 40% in 2026, driven by continuous product approvals and market expansion [1][13] - AK112, a core product targeting PD-1 and VEGF, shows rapid clinical advancement and high safety, particularly in squamous cell carcinoma [14][15] - The company is actively pursuing early treatment research for PD-1 resistant patients, differentiating itself from competitors [2][17] Technological Breakthroughs - Innovations in ADC (Antibody-Drug Conjugates), IO (Immuno-Oncology) bispecific antibodies, GLP-1, and T-cell engagers are leading industry advancements [1][3] - Kangfang's dual antibody technology platform has significantly improved R&D success rates, with rapid approval timelines for key products [13] Investment Insights - Recommended investment targets include companies like Heng Rui Medicine, BeiGene, and others in both A-share and H-share markets [5] - Key investment considerations include overseas sales potential and anticipated business development activities [4] Future Catalysts - For Innovent, upcoming catalysts include the initiation of clinical trials for various products and expected data readouts in 2026 [11] - Kangfang is expected to continue rapid progress in overseas clinical research and expand its market presence [18][24] Market Valuation - Kangfang's current reasonable market value is estimated at 200.098 billion RMB, with a target price of 222.93 RMB based on DCF model calculations [25]

Core Viewpoint - 康方生物 is positioned to lead the next generation of tumor immunotherapy with its innovative dual-antibody platform and strong pipeline of products [1][2][3] Group 1: Company Overview - 康方生物 focuses on developing innovative antibody drugs, utilizing its ACE platform and Tetrabody technology to support over 20 pipelines [1] - The company achieved a significant milestone with the approval of AK104, the world's first PD-1/CTLA-4 dual antibody, in 2022 [1] - 康方生物 has a robust cash position of 7.3 billion RMB in 2024, which supports the commercialization of its pipeline [1] Group 2: Product Pipeline and Market Potential - AK112 has outperformed K drug in head-to-head trials and is expected to become a cornerstone product in the global immuno-oncology market, with peak revenue projections of 17.1 billion RMB by 2035 [2] - AK104 is the only approved PD-1/CTLA-4 dual antibody, with ongoing clinical trials expanding its indications, including cervical and gastric cancers [3] - The company anticipates rapid revenue growth from AK104 and AK112, with projected revenues of 3.67 billion, 5.34 billion, and 7.24 billion RMB for 2025-2027 [4] Group 3: Financial Projections and Valuation - The valuation of 康方生物 is projected at 160 billion HKD based on the potential of AK104 and AK112, with domestic revenue estimated at 3x PS and overseas at 15x PE [4] - The FCFF model indicates a target price of 163.33 RMB, suggesting significant upside potential compared to the closing price on July 7, 2025 [4]

Summary of Key Points from the Conference Call Companies Involved - **Innovent Biologics (1801 HK)** - **Akeso (9926 HK)** Core Insights and Arguments Innovent Biologics - Innovent is positioned as a significant player in the China biopharma sector, focusing on oncology and GLP-1 therapies [4][8] - The company has 16 drugs on the market and approximately 4,000 commercial staff, with expectations to achieve IFRS net-income break-even by 2025 [8] - Projected sales for 2027 could reach RMB 20 billion based on company guidance [8] - Key upcoming events include: - Approval of IBI112 (IL-23p19 inhibitor) for psoriasis in 2H25 [5] - Phase 3 data readout for IBI343 (CLDN18.2 ADC) in 2H25 [5] - Data readout for IBI362 (GLP-1/GCGR) in 2H25/1H26 [5] - IBI363 (PD-1/IL-2α-bias) has shown promising data, with peak sales forecasted at RMB 7 billion in China and RMB 10 billion ex-China [16][8] - The GLP-1 drug mazdutide (IBI362) is expected to capture approximately 11% of the China GLP-1 market, with potential peak sales of RMB 50 billion [8] - Risks include potential pricing cuts, pipeline development setbacks, and competition in the weight loss drug market [8] Akeso - Akeso is recognized as a leading bispecific antibody company in China, having launched the first bispecific drug, AK104 (PD-1/CTLA-4), in 2022 [33][36] - Forecasted peak sales for AK104 in China are around RMB 6 billion, with potential expansions into various cancer indications [36] - AK112 (PD-1/VEGF bispecific) has been out-licensed to Summit Therapeutics, with expected peak sales of over RMB 5 billion in China and over USD 2.5 billion in the US [36] - Upcoming key events for Akeso include: - Sales data for AK104 and AK112 in 1H25 [34] - Detailed data readout for AK112 in various trials in 2H25/1H26 [34] - Concerns exist regarding AK112's commercialization potential in the US due to previous trial results, but there is optimism for improved outcomes with longer follow-up [40] - AK104's efficacy in trials has not been fully appreciated by the market, and a global development plan announcement could enhance investor interest [41][44] Additional Important Content - Innovent's pipeline includes a diverse range of assets across oncology, cardiovascular, autoimmune, and ophthalmology, which supports its growth strategy [12] - Akeso's sales forecasts indicate a strong growth trajectory, with total product sales expected to reach RMB 16.1 billion by 2034 [45] - Both companies face risks related to pipeline development and market competition, which could impact their future performance [8][34]

Investment Rating - The report assigns an "Overweight" (OW) rating to Akeso with a price target of HK$99.00 by December 2025 [2][5]. Core Insights - Akeso's AK104, a PD-1/CTLA-4 bispecific antibody, has received approval in China for first-line treatment of persistent, recurrent, or metastatic cervical cancer, which is expected to significantly boost sales in China [1][4]. - The report anticipates a global development plan for AK104 to be announced in the second half of 2025, which could attract investor interest [1][4]. - Upcoming catalysts include sales figures for AK104 and AK112, the potential global development plan announcement, and detailed data from the HARMONi studies [4][5]. Summary by Sections Approval and Efficacy - AK104's approval is based on strong results from the Phase 3 COMPASSION-16 study, showing a median overall survival (mOS) not reached in the AK104+chemo cohort compared to 22.8 months in the control group, and a median progression-free survival (mPFS) of 12.7 months versus 8.1 months [4]. Market Potential - The report estimates that AK104 could generate approximately RMB 6 billion in peak sales in China, while AK112 is expected to achieve over RMB 5 billion in peak sales in non-small cell lung cancer (NSCLC) [5]. Valuation - The price target of HK$99.00 is based on a discounted cash flow (DCF) valuation, assuming a terminal growth rate of 3.0% and a weighted average cost of capital (WACC) of 9.4% [6].